The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Mr Roll, nothing suspicious. Cant find any RNSs on LSE.
HEMOs pipeline of potential disease killing clinical answers continues. These will be worth billions. I have sold my non performing stocks to allow me to continue adding here ate these crazy cheap prices.
HEMO will continue on this vein. A believe that a JV will shortly be announced that will bring in more than enough cash to get CAR-T trials sorted and then sold for £300 million. In the meantime the company will continue to publish ground breaking science.
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group, announces that it has demonstrated in vivo that its proprietary Chimeric Bait Receptor ("CBR") can be delivered into the brain via programmed microglial cells for the potential treatment of brain cancers and certain neurodegenerative diseases.
Delivery of therapeutics across the blood-brain barrier is one of the most difficult problems in the treatment of brain cancers and certain neurodegenerative diseases. Our scientists at have developed a method of transplantation of human hematopoietic (blood) stem cells ("HSC") that allows their engraftment and differentiation into microglial cells (immune cells that reside in the brain) in the brains of immune-compromised mice.
The Company believes that autologous HSCs that are genetically modified to make CBR and transplanted back to a patient could give rise to microglial cells in the patient's brain. Such microglial cells that have been armed with CBR could potentially be able to find and phagocytose (ingest and destroy) either brain cancer cells or abnormal protein aggregations (e.g., amyloid plaques in Alzheimer's).
The Company's approach described above may offer a number of benefits: (1) it could deliver CBR therapeutics across the blood brain barrier; (2) CBR-armed microglial cells may not be rejected as they are autologous/patient-derived; (3) CBR-armed microglial cells may provide long-term protection of the brain against cancer or protein aggregations because microglial cells live for a long time; and (4) autologous HSC, which are self-renewing, could become an almost unlimited source of CBR-armed microglial cells for the patient.
This is a further indication of the growing range and versatility of CBR as a potential tool against a variety of difficult to treat and deadly conditions.
Research continues on CBR and the Company intends to increase its focus on this once HEMO-CAR-T has entered clinical trials.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "This major breakthrough in the method of delivery of our CBR into the brain is a unique tool that may allow us to successfully tackle some of the most difficult and often incurable human diseases. As we broaden the scope of use for our CBR platform, we are eager to continue its development."
Typo 30%.
This is a Minor Market Misjudgement in the scheme of things. Last year the Market got Rolls Royce 330% undervalued , the day before a Trading Update. Thousands of analysists got it completely wrong. Hardly surprising that a few retail punter's dont understand the true value here.
Micky, your pretending to be a business person that attends meetings . Come on that's funny and deserves a comment.
Is this the sort of language you use in Your Business Meetings
13 Feb 2024 15:25
"it always does after good rns what a load of *******s how the fck can we wait 12 months for ind finaly gets go ahead alsorts of figures "
Micky , how did the meeting go. Glad to see that you are talking an interest in the council estates residents committee.
Now is the time to buy. When the JV RNS hits, if you dint you will regret it.
Who do you Trust, Mr Wood, whose English is pre Primary School level or JHFH. An example of his prose.
Despite what some may think, 30mil valuation for Hemogenyx is NOT realistic.
HEMO-CAR-T have just had approval to enter clinical trials, CAR-T treatments in recent years have been licenced at pre clinical, phase 1, phase 2/3 and after new drug approval. Prices for these licencing agreements are freely available, the vast majority, INCLUDING phase 1 etc, are 500m+ when you include milestone payments. HEMO-CAR-T today with the IND approval is worth easily multiples of the current mCap of Hemogenyx, when trials start IF it works the value becomes multiples and will be known within the first few patients/months.
CDX - basically this is same target market as #AVCT are aiming for, expanding chemo to many more people and reducing the toxic side effects. They want to make Chemo safer, CDX removes chemo altogether but gives same targeted results, Avct have targeted the value at billions? Same applies here, only CDX is better and because its not making EXISTING chemo safer where any revenue would be split, CDX is 100% hemogenyx (Eli Lilly will get some profits from this)
CBR - https://bnnbreaking.com/breaking-news/health/groundbreaking-mrna-therapeutics-breakthrough-room-temperature-stable-treatments-for-global-accessibility I think that makes it clear that even just the approach they have taken makes CBR as an idea worth billions, take the patented CBRs for each virus they can treat? There is no valuation high enough to cover every possibility. Will we ever see true value before its taken out of our hands? Probably not, but I can guarantee you £30m does not even scratch the surface.
100-300m valuation for a CLINICAL pharma with ANY ONE of the above would be cheap, https://sana.com/our-pipeline/ have literally an equivalent to HEMO-CAR-T and they are worth 1.55 BILLION. This current SP/mCap is just stupid, low visibility, lot of traders/shorters and lots of efforts to push the SP over the last week has successfully pushed the SP back down to a stupid price. BUT the shorters cant stay open for ever IG shows 8%, thats alot of shares that need to be bought back to close those positions, This valuation IS WRONG. The current market Valuation IS WRONG. Tick Tock, the rest of the world SLOWLY are starting to notice Hemogenyx, this will only increase as they enter Clinical Trials.
JustHereForHemo Premium Member
Posted in: HEMO
Posts: 4,304
Price: 3.195
No Opinion
RE: Fund raiseToday 10:36
Oh so it might be worth £300 mil? So is it worth £300m or is it NOT worth £300m? Good to see your so decisive here!
So if NOT on CH being lifted when exactly should it re-rate? You do understand that lifting of CH is when the company moved from PRE-CLINICAL to CLINICAL, you know that point where the valuation DOES change?
The market is wrong and has not reacted to the lifting of the hold as it should have YET that does not make it right.
I love it when you get new accounts opened like Mr. Wood . Even better when they have a problem stringing a sentence together. A game changing JV with a major player is on the way. This reminds me of the short period while we were expecting the CH to be lifted. It happened. This time however the SP will shoot up and stay there. Millions of £ s will be invested in HEMO at a premium and investors will clammer to get in.
Clearly as Mickey had a number of recommends, certain people didn't read an earlier post by JHFH. I will repost it for their benefit.
Despite what some may think, 30mil valuation for Hemogenyx is NOT realistic.
HEMO-CAR-T have just had approval to enter clinical trials, CAR-T treatments in recent years have been licenced at pre clinical, phase 1, phase 2/3 and after new drug approval. Prices for these licencing agreements are freely available, the vast majority, INCLUDING phase 1 etc, are 500m+ when you include milestone payments. HEMO-CAR-T today with the IND approval is worth easily multiples of the current mCap of Hemogenyx, when trials start IF it works the value becomes multiples and will be known within the first few patients/months.
CDX - basically this is same target market as #AVCT are aiming for, expanding chemo to many more people and reducing the toxic side effects. They want to make Chemo safer, CDX removes chemo altogether but gives same targeted results, Avct have targeted the value at billions? Same applies here, only CDX is better and because its not making EXISTING chemo safer where any revenue would be split, CDX is 100% hemogenyx (Eli Lilly will get some profits from this)
CBR - https://bnnbreaking.com/breaking-news/health/groundbreaking-mrna-therapeutics-breakthrough-room-temperature-stable-treatments-for-global-accessibility I think that makes it clear that even just the approach they have taken makes CBR as an idea worth billions, take the patented CBRs for each virus they can treat? There is no valuation high enough to cover every possibility. Will we ever see true value before its taken out of our hands? Probably not, but I can guarantee you £30m does not even scratch the surface.
100-300m valuation for a CLINICAL pharma with ANY ONE of the above would be cheap, https://sana.com/our-pipeline/ have literally an equivalent to HEMO-CAR-T and they are worth 1.55 BILLION. This current SP/mCap is just stupid, low visibility, lot of traders/shorters and lots of efforts to push the SP over the last week has successfully pushed the SP back down to a stupid price. BUT the shorters cant stay open for ever IG shows 8%, thats alot of shares that need to be bought back to close those positions, This valuation IS WRONG. The current market Valuation IS WRONG. Tick Tock, the rest of the world SLOWLY are starting to notice Hemogenyx, this will only increase as they enter Clinical Trials.
ReplyRecommend (19)Report Post
pumpky
Posts: 14,267
Price: 3.195
No Opinion
RE: Fund raiseToday 10:47
Not quite Mrs Pumpky has been here years with a 4 pence average "she had purchased a new frock for the 10 pence party:but had to send it back as it will be out of season to wear now!! 😉
ReplyRecommend (1)Report Post
pumpky
Posts: 14,267
Price: 3.195
No Opinion
RE: Fund raiseToday 10:44
MR I:makes a change from you constantly moaning and telling us how bad Vlad is! Have you worked out how much you lost sell
Luckily Mickys opinion isnt based on reality. He has either forgotten about the upcoming JV at a premium to the sp, or he thinks that this wont push the SP over 3.5p. Luckily the more admired posters on this B.B. totally disagree with him. Hmm , trust Micky or JHFH , now that's a hard one.
Ive added about £3k in the last few days , by buying on the dip. I will sell these at the next big spike in the SP, which i believe will be well North of 6p. This will allow me to make a little profit and also to keep the same shareholding , that i had before adding. My long term goal is to in fact gradually increase the number of shares hold, until we are bought out and then i will sell at many multiples of todays price.
Ive now got £20k worth. Im aiming for £500k in the next two years. Better than 5% in the bank.
Worth repeating Basils comment.
Yes NCYT achieving a x 100 would be good to see replicated here with HEMO. We've seen it with other pharma stocks too. PYC accomplished a x 34 multibag in 4 trading days rising from 1p to 34p. 3 months ago TPST went up over x 39. Then of course there's SNG going from 7p to 246p x 35. There's also Sareum going up x 30 from 0.3 to 9p and who can forget Axsome doing x 54 in 12 months? Our sector is full of mega gains. I'm still hopeful of an initial 12-15p, especially with the excellent update today.
When the deal comes and it will, those selling previously will be crying themselves to sleep.
That could happen sooner than we all think.
Just addended another 29456.
The problem is that there are a lot of shorters out there, like the guy that pretends to tell the truth and then knocks the company.